首页> 外文期刊>Pathology oncology research: POR >Relationship between hypermethylated MGMT gene and osteosarcoma necrosis rate after chemotherapy.
【24h】

Relationship between hypermethylated MGMT gene and osteosarcoma necrosis rate after chemotherapy.

机译:MGMT基因甲基化与化疗后骨肉瘤坏死率的关系

获取原文
获取原文并翻译 | 示例
           

摘要

To investigate the relativity of MGMT(O-6-methylguanine-DNA methyltransferase) gene methylation from patients with protein expression and osteosarcoma necrosis rate after chemotherapy. Fifty-one oteosarcoma tissues were collected, Methylation of MGMT gene promoter was detected by methylation-specific PCR method, and protein expression of MGMT was examined by immunohistochemistry procedure, the relationship between methylated MGMT gene expression and patients response to chemotherapy was analyzed. The positive ratio of methylation MGMT gene promoter in 51 patients was 23.5% (12 in 51). Negative percentage of protein expression of MGMT was 27.5% (14 in 51). It seemed that methylation of MGMT gene in osteosarcoma tissues had no evident relationship with the patient's age, sexuality, and the size and type of neoplasms, etc. The necrosis rates of methylated MGMT of osteosarcoma (tumor grade from I to IV) were 0 (0/51), 3.9% (2/51), 5.9% (3/51), 13.7% (7/51), respectively. In contrast, the necrosis rates of unmethylated MGMT of osteosarcoma (tumor grade from I to IV) were 45.1% (23/51), 25.5% (13/51), 3.9% (2/51), 2.0% (1/51), respectively. It suggest that methylated and unmethylated MGMT gene of osteosarcoma have significant difference in protein expression. The unmethylated MGMT gene has higher positive protein expression (u = -4.92, P < 0.001). Methylation of MGMT gene has higher tumor necrosis rate in osteosarcoma patients. Methylation in MGMT promoter may be important for judging the effect of chemotherapy in Osteosarcoma patients.
机译:目的探讨蛋白表达水平和骨肉瘤坏死率的患者MGMT(O-6-甲基鸟嘌呤-DNA甲基转移酶)基因甲基化的相关性。收集五十一个结肠癌组织,通过甲基化特异性PCR方法检测MGMT基因启动子的甲基化,并通过免疫组织化学方法检测MGMT的蛋白表达,分析甲基化MGMT基因表达与患者对化疗反应的关系。甲基化MGMT基因启动子的阳性率在51名患者中为23.5%(51名中的12名)。 MGMT蛋白表达的负百分比为27.5%(51中的14)。骨肉瘤组织中MGMT基因的甲基化似乎与患者的年龄,性别,肿瘤的大小和类型等无明显关系。骨肉瘤的甲基化MGMT(肿瘤分级为I至IV)的坏死率为0( 0/51),3.9%(2/51),5.9%(3/51),13.7%(7/51)。相反,骨肉瘤未甲基化的MGMT(肿瘤级别从I到IV)的坏死率为45.1%(23/51),25.5%(13/51),3.9%(2/51),2.0%(1/51) ), 分别。这提示骨肉瘤的甲基化和未甲基化的MGMT基因在蛋白质表达上有显着差异。未甲基化的MGMT基因具有较高的阳性蛋白表达(u = -4.92,P <0.001)。 MGMT基因的甲基化在骨肉瘤患者中具有较高的肿瘤坏死率。 MGMT启动子中的甲基化对于判断骨肉瘤患者化疗的效果可能很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号